Table 1.
Infarct Size and Hemodynamics in 2- or 7-Day Gevokizumab Treatments in Wistar Rats
| Time | Sham Treatment | Ischemia/Reperfusion |
||
|---|---|---|---|---|
| Untreated | Gevokizumab Treated | |||
| LV weight, g | D0–2 | – | 0.79 ± 0.07 | 0.66 ± 0.04 |
| D0–7 | 0.65 ± 0.02 | 0.64 ± 0.02 | 0.66 ± 0.03 | |
| Area at risk, % of LV | D0–2 | – | 45.2 ± 3.4 | 45.6 ± 1.9 |
| Necrotic area, % of LV | D0–2 | – | 25.9 ± 2.7 | 8.5 ± 0.3† |
| Infarct size, % of LV | D0–7 | – | 42.9 ± 2.6 | 34.0 ± 2.9† |
| LV ESP, mm Hg | D0–2 | – | 84.6 ± 5.5 | 100.4 ± 6.8† |
| D0–7 | 130.1 ± 1.6 | 101.9 ± 7.0∗ | 119.6 ± 5.1† | |
| LV ESVRP, mm Hg/RVU | D0–2 | – | 14.4 ± 0.8 | 16.8 ± 0.5† |
| D0–7 | 24.1 ± 0.64 | 12.3 ± 1.2∗ | 15.5 ± 0.9† | |
| LV EDP, mm Hg | D0–2 | – | 2.68 ± 0.53 | 1.96 ± 0.19† |
| D0–7 | 1.87 ± 0.59 | 4.09 ± 0.57∗ | 3.19 ± 0.59 | |
| LV EDPVR, mm Hg/RVU | D0–2 | – | 1.81 ± 0.15 | 1.43 ± 0.09† |
| D0–7 | 0.89 ± 0.11 | 2.10 ± 0.22∗ | 1.66 ± 0.16† | |
Values are mean ± SD.
D0–2 = 2-day treatment initiated 1 h after I/R; D0–7 = 7-day treatment initiated 1 h after I/R; LV EDP = left ventricular end-diastolic pressure; LV EDPVR = left ventricular end-diastolic pressure-volume relationship; LV ESP = left ventricular end-systolic pressure; LV ESPVR = left ventricular end-systolic pressure-volume relationship; LV = left ventricular; RVU = relative volume units.
∗
p < 0.05 versus sham.
†
p < 0.05 versus untreated I/R. n = 4 to 17 per group.